NCT01714336 - Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery? | Biotech Hunter

Enrollment

138

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Hip Fracture

Interventions

DRUG

tranexamic acid

Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.

DRUG

placebo

A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester